• mv-slider
  • lazy: true
HOME
サブ-ナビゲーション
  • information
  • News
  • Corporate Guide
  • Business
  • Investor Relations
  • Sustainability
  • Contact Us

HOME

NEWS

  • What’s new
  • Press Release
  • Investor Relations
  • Information
  • 2025/05/13 Notice of Changes in Representative Directors pdf （140KB）
  • 2025/05/13 Notice Concerning Dividend from Surplus pdf （137KB）
  • 2025/05/13 Consolidated Financial Results for the FY Ended March 31 2025 pdf （478KB）
  • 2025/05/01 (Progress of Matters Previously Disclosed) Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary pdf （233KB）
  • 2025/03/28 [Delayed] Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary pdf （267KB）
  • Read More
  • 2024/06/27 Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
  • 2023/11/13 Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
  • 2023/10/12 Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
  • 2023/10/05 Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
  • 2023/10/03 Takara Bio Announces Presentation of Comparability Studies for CD19 JAK/STAT CAR-T Cell Technology Transfer
  • Read More
  • 2025/05/13 Notice of Changes in Representative Directors pdf （140KB）
  • 2025/05/13 Notice Concerning Dividend from Surplus pdf （137KB）
  • 2025/05/13 Consolidated Financial Results for the FY Ended March 31 2025 pdf （478KB）
  • 2025/05/01 (Progress of Matters Previously Disclosed) Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary pdf （233KB）
  • 2025/03/28 [Delayed] Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary pdf （267KB）
  • Read More
  • 2024/05/02 Takara Bio to Present Advances in Gene and Cell Research at ASGCT 2024
  • Read More

BUSINESS

  • Read More

Research reagents

Scientific instruments

CDMO

Gene Therapy

INVESTORRELATIONS

  • Read More

SUSTAINABILITY

  • Read More

COMPANY

  • Read More

PAGETOP
PAGETOP
  • CLOSE
  • MENU

サイト内検索

  • footer-content
  • menu
  • JA
  • EN
  • contact
  • gnavi-box